TS-01 is under clinical development by Thrombolytic Science International and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect TS-01’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 17 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TS-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
TS01 is under development for the treatment of acute ischemic stroke and myocardial infraction. The drug candidate composed of HisproUK, a single-site mutant of native proUK preceded by the administration of the natural plasma inhibitor, C1 esterase inhibitor. It is administered intravenously. The drug candidate acts on plasminogen, thus it converts the plasminogen to plasmin.
Thrombolytic Science International overview
Thrombolytic Science International (TSI) is a clinical-stage vascular medicine and biotechnology company that focuses on the development of novel medicines for the treatment of thrombotic diseases. The company offers TS01, a therapeutic regimen composed of low, fractional doses of tPA and mproUK. TSI utilizes its tPA/prourokinase (proUK) thrombolytic mechanism in vitro for animal studies, and is validated by clinical studies in patients with heart attacks. The company is focused on the development of proUK, an inactive compound, a proenzyme that targets the occlusive clot exclusively and it converts to its enzymatic form. TSI is headquartered in Cambridge, Massachusetts, the US.
Quick View TS-01 LOA Data
|Highest Development Stage|